Stockreport

Nuvation Bio secures $250m for taletrectinib commercialisation [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF The financial move will support Nuvation Bio's present clinical-stage pipeline development. It offers potential profitability without requiring additional capital raisi [Read more]